COMPREHENSIVE TUMOR PROFILING FOR PRECISION MEDICINE

COMPREHENSIVE TUMOR PROFILING FOR PRECISION MEDICINE

Genomic medicine is rapidly changing the future of medicine. 

GENEVOLVE –the Genomic division of Dr Lal PathLabs Ltd, with a focused foray into Genetic testing has brought the dawn of a new era of Genomic testing.

GENEVOLVE offers a wide range of key tests related to Oncogenomics, Neurogenomics, Rare disease & Pre-natal/Post-natal genetic testing using cutting edge technologies such as Next Generation Sequencing (NGS), MLPA, ddPCR, FISH & Sanger Sequencing, etc.

Personalized and precise information to improve healthcare for everyone is the call of today’s medical world. Being a pioneer in patient care, Dr Lal PathLabs Ltd has started a collaboration with  Caris Molecular Intelligence^®, Caris Life Science’s patented and proprietary offering.

Redefining Cancer Diagnosis -Historically cancer medicine studies grouped patients according to cancer type and stage rather than by  their individual cancer’s characteristics.

The dilemma? Cancers in the same part of the body, or even the same stage, might be very different on a molecular or genetic level and may respond very differently to various treatments. And, cancers in different parts of the body can respond more similarly to certain treatments than expected. These molecular and genetic similarities and differences are dictated by Biomarkers- proteins, genes and other molecules that affect how cancer cells grow, multiply, die and respond to other compounds in the body. So, profiling your cancer to identify biomarkers may help your physician to better evaluate your therapy selection.

Caris Molecular Intelligence^® uses multiple tumor profiling technologies to decode cancer and better understand the biology driving tumor growth. The biomarker results, or molecular profile, from a tissue sample are then matched to cancer drugs associated with benefit or lack of benefit, as well as clinical trials, for your unique cancer.  The profiling can be useful for people who have been diagnosed with a solid tumor cancer and your physician is seeking additional treatment information when:

• your cancer has metastasized or recurred;
• you are facing aggressive or rare cancer;
• your physician is navigating multiple treatment options; or
• you have run out of standard treatment options to fight your cancer.

Caris Life Sciences® offerings assess DNA, RNA and proteins to reveal a molecular profile that helps physicians and cancer patients make more precise and personalized treatment decisions. MI Exome™ whole exome sequencing with 22,000 DNA genes, and MI Transcriptome™ whole transcriptome sequencing with 22,000 RNA genes along with cancer-related pathogens, bacteria, viruses and fungi analysis run on every patient provides the most comprehensive and clinically relevant DNA and RNA profiling available on the market.

Caris is also advancing precision medicine with Caris MAI™ (Molecular Artificial Intelligence) that combines its innovative service offerings, Caris Molecular Intelligence® with its’ proprietary artificial intelligence analytics engine, DEAN™, to analyze the whole exome, whole transcriptome and complete cancer proteome.

This information, coupled with mature clinical outcomes on thousands of patients, Caris Life Sciences’ Precision Oncology Alliance with 37 leading cancer centers and 20 active Biopharma relationships, has solutions that provide oncologists with the most clinically actionable treatment options available to personalize cancer care today. Caris is a molecular oncology research leader with 250+ posters and presentations, 100+ publications and many collaborations with research and academic institutes.

Why is Caris your trusted molecular profiling partner?

Unlike other tests Caris Molecular Intelligence^® is a Comprehensive Molecular Profiling service assessing DNA, RNA and Proteins with multiple technologies (NGS DNA WES & RNA WTS, Pyrosequencing , IHC and ISH) to reveal the highest quality molecular profile to guide more precise and individualized treatment decisions that can extend overall patient survival.

USPs of Caris Molecular Intelligence^®:

✔  Unmatched experience around DNA, RNA and proteins

• 2,800,000 + tests completed
• 225,000+ clinical cases performed

✔  Immunotherapy Dx Expertise

• PD-L1 by IHC, including TPS and CPS scoring methods
• Mismatch Repair (MMR) proteins by IHC: MLH1, MSH2, MSH6, PMS2
• Microsatellite Instability (MSI) by NGS
• Tumor Mutational Burden (TMB) by NGS

✔  Rigorous Quality Standards

• CAP, CLIA, NYSDOH, ISO15189 accredited
• 66,000-square-foot clinical laboratory in Phoenix, Ariz.;
• 115,000-square-foot blood-based laboratory in Irving, Texas (to open in 2020)
• Staffed by: bioinformaticians, oncologists, molecular geneticists, pathologists and PhD scientists

✔  Tissue Testing capabilities

• Tumor enrichment via microdissection
• Multiple reflex options to alternative technologies/methods

✔   Rapid Turnaround Time

With the promise of precision medicine becoming a reality, molecular profiling has become standard of care for many cancer types – and required for certain therapies (companion dx). More than ever, oncologists need a trusted tumor profiling partner to provide reliable, high-quality molecular information to guide more precise and individualized treatment decisions and we at Dr Lal PathLabs Ltd , Genevolve division, offer this by joining hands with Caris Molecular Intelligence^®

KEY TESTS RANGE

MI Profile™ and MI Tumor Seek™ offer Solid Tumor Biomarker Analysis for therapeutic decision support.